News

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, announced a hearing titled Legislative Proposals to Support Patient Access to Medicare Services.

Subcommittee on Health hearing titled Legislative Proposals to Support Patient Access to Medicare Services.

WHAT: Subcommittee on Health hearing to discuss legislation focused on improving Medicare payment policies and expanding access to care for seniors.

DATE: Thursday, January 8, 2026

TIME: 10:15 AM ET

LOCATION: 2123 Rayburn House Office Building

This hearing will focus on the following bills:

• H.R. 1703, Choices for Increased Mobility Act of 2025 (Rep. Joyce – PA)
• H.R. 2005, DMEPOS Relief Act of 2025 (Rep. Miller-Meeks)
• H.R. 2172, Preserving Patient Access to Home Infusion Act (Rep. Buchanan)
• H.R. 2477, Portable Ultrasound Reimbursement Equity Act of 2025 (Rep. Van Duyne)
• H.R. 2902, Supplemental Oxygen Access Reform (SOAR) Act of 2025 (Rep. Valadao)
• H.R. 5243, To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage. (Rep. McClellan)
• H.R. 5269, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 (Rep. Hudson)
• H.R. 5347, Health Care Efficiency Through Flexibility Act (Rep. Buchanan)
• H.R. 6210, Senior Savings Protection Act (Rep. Matsui)
• H.R. 6361, Ban AI Denials in Medicare Act (Rep. Landsman)

This notice is at the direction of the Chairman. This hearing will be open to the public and press and will be livestreamed at energycommerce.house.gov. If you have any questions about this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov. If you have any press related questions, please contact Katie West at Katie.West@mail.house.gov.

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Subcommittee Republicans, wrote to National Institutes of Health (NIH) Director Monica Bertagnolli. In the letter, the Chairs ask the NIH to confirm by May 14, 2024, whether the agency has complied with White House guidance to stop funding projects led by researchers and entities in Russia.  BACKGROUND :  On June 11, 2022, the White House Office of Science and Technology Policy (OSTP) issued guidance stating such projects and programs that commenced and/or were funded prior to Russia’s further invasion of Ukraine in February 2022 may be concluded, but new projects in affected subject areas will not be initiated.   The OSTP advised applicable departments and agencies to curtail interaction with the leadership of Russian government-affiliated universities and research institutions, as well as those who have publicly expressed support for the invasion of Ukraine.  In a statement in an April 9, 2023, article in The Washington Times , the NIH’s Office of Extramural Research claimed that “NIH currently does not fund any research in Russia.”  However, the Data Abyss tracker for the OSTP Russia guidance on federal funding agencies indicates that, as of April 5, 2024, the NIH has potentially 240 instances of problematic research collaborations since June 2022 that do not comply with the guidance. CLICK HERE to read the letter.

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Subcommittee Republicans, wrote to Department of Health and Human Services (HHS) Secretary Xavier Becerra.  The letter outlines concerns with the role HHS Office of Civil Rights (OCR) plays—or fails to play—in investigating instances of sexual harassment that occurs at research institutions which receive grants from the National Institutes of Health (NIH).  KEY EXCERPTS :  “There have been several public reports of sexual harassment occurring on NIH-funded research or NIH-supported activities over the last decade, and it raises concerns about what, if any, actions the NIH has taken to resolve these issues. The NIH’s own statistics show a significant problem with more than 300 cases related to sexual or gender harassment since 2018—with about a third of those allegations being substantiated. This also represents hundreds of men and women who may be forced to operate in a hostile or unsafe research environment.”  [...]  “According to the HHS website, OCR does investigate and resolve complaints of sexual harassment in the education and health programs of recipients of grants or other federal financial assistance from HHS—including the NIH. Moreover, HHS OCR is required to conduct periodic compliance reviews of institutional Title IX programs to ensure compliance with the law—including examining the way in which complaints are handled by the institution.”  The Chairs have requested answers to questions about HHS OCR’s role by April 30, 2024.  BACKGROUND :  Based on a recommendation from the U.S. Government Accountability Office (GAO), HHS OCR and the NIH adopted a memorandum of understanding (MOU) to facilitate communication between the two components of HHS as it relates to sexual harassment.   This MOU was intended to clarify procedures on how the enforcement arm of HHS and the grant-making arm share valuable information with one another in an effort to respond appropriately to complaints of sexual harassment and prevent federal grant money from going to those with a history of sexual misconduct.   TIMELINE OF INVESTIGATION :  August 10, 2021 : E&C Republican Leaders Question NIH’s Handling of Sexual Harassment Complaints  August 11, 2022 : E&C Republican Leaders follow up with NIH on Insufficient Response to its Letter on the NIH’s handling of Sexual Harassment  November 30, 2022 : E&C Republicans to NIH: Turn Over Previously Requested Information Ahead of New Congress  March 14, 2023 : E&C Republicans Press NIH for Information on Handling of Sexual Harassment Complaints  October 6, 2023 : E&C Republicans Signal Intent to Issue Subpoenas to Obtain Information on NIH’s Handling of Sexual Harassment if Questions Go Unanswered  January 26, 2024 : Chair Rogers notifies NIH of Imminent Subpoena  February 5, 2024 : Chair Rodgers Subpoenas NIH for Documents Related to Investigation into Sexual Harassment at NIH and NIH Grantee Institutions February 20, 2024: HHS Responds on behalf of NIH to offer a rolling in camera document review to the Committee. Documents produced in the review have been highly redacted, including the redaction of the names of individuals convicted of criminal offenses, public news articles about individuals who have been found guilty of harassment, and redaction of the names of the institutions where the abuse occurred—effectively preventing the Committee from understanding if NIH continues to fund work performed by substantiated abusers at other institutions—a practice known as “pass the harasser.”

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight subcommittee Republicans, wrote to Food and Drug Administration (FDA) Commissioner Robert Califf regarding how the agency handles internal scientific disagreements. Of particular concern to the Committee is whether FDA scientists face possible retaliation for expressing differing scientific views. In the letter, the Chairs note they are prepared to pursue compulsory measures should the FDA fail to respond in a timely, good-faith manner. KEY LETTER EXCERPTS : “ [I]n August 2021, the FDA announced two top vaccine regulators were leaving the agency. One reason cited for the departures was that they were upset about the Biden administration’s announcement that adults should get a coronavirus booster vaccination eight months after they received their second shot. Neither reportedly believed there was enough data to justify offering booster shots yet, and both viewed the announcement by President Biden as pressure on the FDA to authorize the shots quickly. It is unknown whether the FDA dispute resolution process was used, and if not, why not. We are concerned that the FDA may have retaliated against career FDA regulators who were viewed as insufficiently cooperative with the Biden administration’s agenda. ” […] “Given the renewed interest in updated scientific integrity policy, the Committee seeks information on the adequacy of the FDA’s existing policies for handling scientific disagreements, and whether FDA leadership has taken retaliatory actions against dissenting FDA officials." BACKGROUND : A September 2023 Government Accountability Office (GAO) report highlighted the Department of Health and Human Services’ (HHS) interest in developing processes for differing scientific opinions. The GAO also noted that the FDA has existing dispute resolution policies and may continue to use them when the updated scientific integrity policy is finalized. In addition, the GAO has issued two other recent reports that are pertinent to the FDA’s handling of internal scientific disagreements. In June 2012, the HHS Office of Inspector General (OIG) issued a study, Scientific Disagreements Regarding Medical Device Regulatory Decisions . The OIG found that accountability for the completeness of administrative files related to scientific disagreements was unclear as Not all Center for Devices and Radiological Health (CDRH) managers and reviewers received training on the new procedures CDRH faced broader challenges in identifying and resolving scientific disagreements because of uncertainty about regulatory definitions and processes and staff perceptions about expressing differences of opinion Further, the OIG recommended that the FDA: (1) define more clearly its requirements for documenting and resolving scientific disagreements (2) train all reviewers and managers on the new policies and procedures for resolving scientific disagreements (3) more clearly assign accountability for the contents of the administrative files of all submissions The FDA concurred with all three recommendations. The Chairs requested a response with the following information by January 17, 2024:  Copies of the administrative files related to all internal scientific disagreements at the FDA since January 1, 2018, documenting whether and/or how the resolution was reached and the basis, including any joint memoranda. All documents since January 1, 2018, related to the Office of Chief Scientist handling of appeals of internal scientific disagreements at the FDA. All documents related to the scientific disagreement within the FDA over coronavirus booster vaccination during summer 2021. If the internal process was not used, please provide all documents related to any changes in decision-making authority on the coronavirus booster vaccination during summer 2021 (e.g., authority removed from the director and deputy director of the Center for Biologics Evaluation and Research (CBER) vaccines office and reassigned to the CBER director). All documents since January 1, 2018, related to all instances where decision-making authority was removed from FDA officials involved in regulatory decisions. CLICK HERE to view the full letter.

Chairs signal intent to subpoena if FDA continues stonewalling crucial request Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffth (R-VA), on behalf of the Health and Oversight Republicans, sent a letter to Food and Drug Administration (FDA) Commissioner Robert Califf. The letter follows up on a previous request for information related to the agency’s foreign drug inspection program and comes amid the Committee’s work to address drug shortages . To date, the FDA has not provided any response to the Committee.  KEY LETTER EXCERPT :  “The U.S. cannot afford additional disruptions to the drug supply chain that reduce the availability of essential medications and force doctors and patients to make difficult treatment decisions. Members of this Committee have repeatedly expressed concern regarding the effectiveness of the FDA’s foreign drug inspection program, including at two separate hearings this Congress before the Subcommittee on Oversight and Investigations and the Subcommittee on Health. Addressing drug shortages remains a top priority for the Committee.”  BACKGROUND :  Since the Committee’s July letter to the FDA, there have been additional drug recalls from Indian manufacturers and plant closures in the United States.   In August, Indian drug manufacturers, Alembic and Aurobindo Pharma, issued voluntary drug recalls citing quality and manufacturing deficiencies, respectively.   Alembic recalled over 80,000 bottles of tobramycin, used to treat bacterial eye infections, due to “failed impurities/degradation specifications.”  Aurobindo recalled rufinamide tablets used to treat seizure disorders.  Both companies have a history of drug recalls and quality control failures.   Last year, the FDA issued Alembic a Form 483, which cited its manufacturing plant in Panelav, Gujarat with four observations following a 10-day inspection.  It has come to light that the FDA ended its unannounced foreign inspection program out because the agency believed it was an obstacle to deeper collaboration with India.   The reporting also alleges that the FDA undermined a Department of Defense initiative to independently test the quality of imported drugs used by the military out of fear that it would undermine the FDA’s credibility.   In addition, a newly published study has confirmed that FDA foreign inspections in 2022 were down 79 percent compared to 2019 while at the same time the number of “citations rose dramatically, despite all establishments being given advance notice of inspections.”   ADDITIONAL BACKGROUND :  Domestic production of vital medicines continues to be under stress.   In early August, Pfizer announced it would limit the distribution of injectable drugs manufactured at its North Carolina plant after the facility suffered damage in the aftermath of a tornado.   In September, autoinjector maker Aktiv Pharma Group (“AktiVax, Inc.”), which produces autoinjectors to treat life threating conditions, announced the closure of three manufacturing facilities.   Just last year, the company w as awarded over $45 million to supply a nerve agent antidote to the Strategic National Stockpile. While shortages of cancer drugs appear to have eased slightly in recent months, demand continues to outstrip supply .  The Chairs are prepared to issue a subpoena if the FDA does not produce the requested documents January 5, 2024. CLICK HERE to read the letter.

Letter comes ahead of Director Cohen’s testimony before Oversight Subcommittee Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight subcommittee Republicans, today wrote to Centers for Disease Control and Prevention Director Mandy Cohen, who is slated to testify before the Oversight Subcommittee tommorrow, November 30. KEY LETTER EXCERPTS :  “ The Centers for Disease Control and Protection’s (CDC) failure to communicate accurate information in real-time during the COVID-19 pandemic has undermined public trust in the agency. If the CDC is to regain credibility with the American people, it must be transparent and forthcoming with the information it has on public health threats facing our nation. “It is widely known that China thwarted international efforts, including efforts by the CDC, to respond to the burgeoning COVID-19 crisis as it began to unfold in China. Even the World Health Organization (WHO), which has long been criticized for being overly accommodating to the Chinese Communist Party (CCP), has called China’s decision to withhold information from the early days of the COVID-19 pandemic ‘simply inexcusable.’ “The WHO has now called on China to provide epidemiologic and clinical information, as well as laboratory results, on the reported pneumonia clusters among children, in addition to information on recent trends of known pathogen circulation. It would be an abdication of the CDC’s duty to the American people if it allows China to repeat its misdeeds from the COVID-19 pandemic. The American people should not have to rely on the unaccountable and untrustworthy WHO to communicate information about Chinese public health threats. Further, we cannot allow the CCP to block the CDC from accessing the information it needs to protect Americans and assist in appropriate public health response efforts.”  The Chairs requested bi-weekly briefings and answers to the following questions by December 13, 2023:  Has the CDC engaged with or interacted with its Chinese counterparts with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia?  If yes, when did the CDC and its Chinese counterparts first interact with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia? Who initiated this interaction?  At any point did the CDC’s Chinese counterparts withhold information or fail to respond to the CDC in a timely manner with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia? Please detail each instance and the topic of inquiry that prompted such failure to respond in a timely manner. What specific information, if any, has the CDC sought from China with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia? What specific information, if any, has the CDC received from China with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia? Please detail the length of time it took China to respond to each inquiry for information. What specific response efforts, if any, has the CDC offered to take part in with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia?  What specific response efforts, if any, has the CDC taken part in, is actively taking part in, or plans to take part in with respect to the increased incidence of respiratory diseases and undiagnosed pneumonia?  Has specific information on the outbreak been communicated to relevant federal agencies and/or key stakeholders, including:  The Administration for Strategic Preparedness and Response (ASPR);  The U.S. Food and Drug Administration (FDA);  The National Institutes of Health (NIH); The Surgeon General; Department of Defense; Other Federal entities; and/or  State and local public health officials CLICK HERE to read the letter.

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Health Chair Brett Guthrie (R-KY) announced a subcommittee hearing on policies to improve patient access to care and support providers. “Our health care sector continues to find new innovative treatments—yet seniors on Medicare can be left without access to the best care. Further, Congress must continue working on proposals that ensure Medicare beneficiaries can receive physician care and laboratory testing services where they live,” said Chairs Rodgers and Guthrie. “This markup takes the next step toward delivering solutions, and we thank our Members for leading on policies that will help seniors lead longer, healthier lives.”  WHAT : A Subcommittee on Health markup of 21 legislative proposals. DATE : Wednesday, November 15, 2023 TIME : 10:00 AM EDT LOCATION : 2123 Rayburn House Office Building  This notice is at the direction of the Chair. The hearing will be open to the public and press and will be live streamed online at https://energycommerce.house.gov/ . If you have any questions concerning the hearing, please contact Jolie Brochin with the Committee staff at Jolie.Brochin@mail.house.gov . If you have any press-related questions, please contact Christopher Krepich at Christopher.Krepich@mail.house.gov . Legislative proposals to be considered :  H.R. 5372 , Expanding Seniors’ Access to Lower Cost Medicines Act of 2023 (Reps. Joyce and Peters)  H.R. 2880 , Protecting Patients Against PBM Abuses Act (Reps. Carter and Blunt Rochester)  H.R. 5393 , To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes (Reps. Griffith and Carter)  H.R. 5385 , Medicare PBM Accountability Act (Reps. Landsman and Harshbarger)  H.R. 5386 , Cutting Copays Act (Reps. McGarvey and Bilirakis)  H.R. 4881 , To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. (Reps. Malliotakis and Wenstrup) H.R. 5389 , National Coverage Determination Transparency Act (Reps. Guthrie and Kelly)  H.R. 133 , Mandating Exclusive Review of Individual Treatments (MERIT) Act (Reps. Buchanan and Barragan)  H.R. 5396 , Coverage Determination Clarity Act of 2023 (Rep. Bucshon)  H.R. 5371 , Choices for Increased Mobility Act of 2023 (Reps. Joyce and Phillips)  H.R. 5388 , Supporting Innovation for Seniors Act (Reps. Balderson and Buchanan)  H.R. 5380 , To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage (Rep. Sarbanes)  H.R. 3842 , Expanding Access to Diabetes Self-Management Training Act of 2023 (Reps. Schrier, Bilirakis, and Bucshon)  H.R. 5397 , Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick, Dunn, and Soto)  H.R. 6366 , To amend title XVIII of the Social Security Act with respect to the work geographic index for physician payments under the Medicare program, and to revise the phase-in of clinical laboratory test payment changes under such program (Rep. Hudson)  H.R. 6369 , To amend title XVIII of the Social Security Act to extend incentive payments for participation in eligible alternative payment models (Reps. Schrier and Dunn)  H.R. 5555 , DMEPOS Relief Act of 2023 (Reps. Miller-Meeks and Tonko)  H.R. 6371 , Provider Reimbursement Stability Act of 2023  (Reps. Murphy, Burgess, Kelly, Wenstrup, Buschon, Van Drew, Miller-Meeks, Harris, Babin, Joyce, Jackson, McCormick, Ferguson, Dunn, and Carter)  H.R. 6364 , Medicare Telehealth Privacy Act of 2023 (Reps. Balderson, Dunn, Schweikert, Carey, and Johnson)  H.R. 1352 , Increasing Access to Biosimilars Act of 2023 (Rep. Hudson)  H.R. 1691 , Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (Reps. Wenstrup, Bilirakis, Cardenas, Guthrie, and Eshoo) 

Washington, D.C. — In a final warning to the Food and Drug Administration (FDA), House Energy and Commerce Committee Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Subcommittee Republicans, threatened to issue a subpoena for documents related to risky research conducted at FDA facilities. The letter follows two previous requests for documents regarding experiments involving virus manipulation, which the FDA has acknowledged occurred in some of its research studies.   November 9, 2023  The Honorable Robert M. Califf, M.D., MACC  Commissioner  U.S. Food and Drug Administration  10903 New Hampshire Avenue  Silver Spring, MD 20903  Dr. Califf,  The Committee sent the U.S. Food and Drug Administration (FDA) a letter on March 27, 2023, regarding FDA-funded research that may pose significant biosafety or biosecurity risks. Following the FDA’s insufficient response on May 26, 2023, we sent a follow up letter on June 29, 2023. To date, the FDA has only produced 29 pages of the charter documents for the Institutional Biosafety (IBC) and the Dual Use Research of Concern (DURC) review panel, which were not sent until October 20, 2023. Having not received an adequate response to our follow-up letter, we are sending a formal document request to obtain information needed for our oversight that we requested in the June 29 letter.  Pursuant to Rules X and XI of the U.S. House of Representatives, please provide the following by November 28, 2023:  All coronavirus research studies referenced in the January 31, 2023, email. All studies that have undergone Institutional Biosafety Committee (IBC) review at the FDA since October 1, 2013, and all documents related to the IBC reviews of these studies.   All studies that have undergone Dual Use Research of Concern (DURC) review at the FDA since October 1, 2013, and all documents related to the DURC reviews of these studies.   All policies and/or procedures related to the IBC and DURC processes.   In the May 26, 2023, response letter, the FDA stated that the Center for Biologic Evaluation and Research (CBER) research studies involving coronaviruses and viral manipulation of SARS-CoV-2 “underwent applicable Institutional Biosafety Committee (IBC) review, including attestation by the principal investigator (PIs) regarding Dual Use Research of Concern (DURC) screening.” The FDA added “[n]one of these studies rose to the level of DURC review.” Please provide all documents related to these statements.  In the May 26, 2023, response letter, the FDA stated that a Center for Drug Evaluation and Research (CDER) laboratory performs studies to monitor and evaluate seasonal influenza virus resistance to clinically relevant antivirals. Please provide all documents related to these studies, including the IBC and DURC applications and approvals.   In the May 26, 2023, response letter, FDA stated that FDA requires “any research associated with hazardous biological agents and toxins (HBATs) be subject to full IBC review.” Please provide all documents since October 1, 2013, associated with HBATs, including documents related to full IBC review.  In the May 26, 2023, response letter, the FDA stated that “[s]ince September 2015, and prior to the establishment of the DRP, the FDA’s IBC application process required the attestation of all PIs concerning the nature of their work as it related to DURC policies.” Please provide a copy of the IBC application with the attestation requirement, and all documents related to the establishment of the attestation requirement.  All documents related to all extramural research that have gone through the FDA IBC and/or DURC review since September 1, 2015.    Thus, to carry out our Constitutional responsibilities of oversight, if the FDA does not produce the requested documents by November 23, 2023, it will be necessary to issue a subpoena for documents since the FDA has delayed its response and the committee has a right to obtain these materials to aid in its legislative activities and to ensure that the Executive Branch is complying with the law.  If you have any questions, please contact the Majority Committee staff at (202) 225-3641. Thank you for your attention to this request.  CLICK HERE to view the letter.  CLICK HERE to read the March 27, 2023. letter.  CLICK HERE to read the June 29, 2023, letter. 

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Subcommittee Republicans, sent a letter to the Substance Abuse and Mental Health Services Administration. The letter to Assistant Secretary and Administrator Delphin-Rittmon, which is the second follow up from the Committee, serves as the final notice before the Committee will be forced to issue a subpoena. KEY EXCERPTS :  “[…] SAMHSA still has not yet provided the full accounting for billions of dollars in expenditures as requested.”  […]  “Since SAMHSA apparently is not addressing our requests for expenditure information, we now request documents. The Committee’s document requests are specific and reasonable and seek to get full accountability for SAMHSA funds. Unfortunately, SAMHSA has repeatedly not provided requested information about expenditures, nor have any legal reasons been provided for not yet providing the requested information and documents.”  The Chairs requested the following documents by November 27, 2023:  The most recent copies of each state’s Payment Management System and Federal Financial Report draw-down reports for COVID supplemental funding. The most recent copies of Payment Management System and Federal Financial Report draw-down reports for each of the following programs that received COVID-19 supplemental funds: Certified Community Behavioral Health Clinics (CCBHCs); Suicide Prevention Programs; Project AWARE; Tribal Behavioral Health Grants; Substance Use Prevention, Treatment, & Recovery Services Block Grant; Community Mental Health Services Block Grant; National Childhood Traumatic Stress Network; and Community Based Substance Use Disorder Services The most recent copies of each state’s Payment Management System and Federal Financial Report draw-down reports for 9-8-8 crisis care funding.  CLICK HERE to read the full letter.  CLICK HERE to read the Chairs’ April 5, 2023, letter on Covid Spending, Suicide Hotline Rollout, Support for Treating Serious Mental Illness, and New Office of Recovery. CLICK HERE to read the Chairs’ August 10, 2023, follow up letter.